ethacrynic acid Side Effects
Also known as: Edecrin
Analysis of 520 adverse event reports submitted to the FDA from 1997 to 2025.
Total Reports
520
Death-Related
64
12.3% of reports
Hospitalizations
212
40.8% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 64 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 24 |
| FATIGUE | 9 |
| PYREXIA | 9 |
| CONSTIPATION | 6 |
| RESPIRATORY DISTRESS | 6 |
| TOXIC EPIDERMAL NECROLYSIS | 6 |
| VOMITING | 6 |
| ACUTE KIDNEY INJURY | 5 |
| APLASIA PURE RED CELL | 5 |
| ASPIRATION | 5 |
| CARDIAC FAILURE | 5 |
| DEVELOPMENTAL DELAY | 5 |
| ENTEROCOCCAL INFECTION | 5 |
| HAEMOGLOBIN DECREASED | 5 |
| LYMPHOCYTOSIS | 5 |
| NO THERAPEUTIC RESPONSE | 5 |
| RASH | 5 |
| STAPHYLOCOCCAL INFECTION | 5 |
| TRANSPLANT REJECTION | 5 |
| WHEEZING | 5 |
Reactions in Hospitalization Reports
Top reactions in 212 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS | 46 |
| OFF LABEL USE | 30 |
| PNEUMONIA | 19 |
| ACUTE KIDNEY INJURY | 18 |
| DIARRHOEA | 18 |
| DYSPNOEA | 18 |
| DRUG HYPERSENSITIVITY | 17 |
| FATIGUE | 16 |
| NAUSEA | 14 |
| MALAISE | 13 |
| ASTHENIA | 12 |
| DRUG INEFFECTIVE | 11 |
| HYPOTENSION | 11 |
| PYREXIA | 11 |
| WEIGHT DECREASED | 11 |
| PRODUCT USE IN UNAPPROVED INDICATION | 10 |
| SEPSIS | 10 |
| VOMITING | 10 |
| ANAEMIA | 9 |
| CARDIAC FAILURE | 9 |
Nearby — Related Medications
What the FAERS Data Reveals About ethacrynic acid Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 520 voluntary reports linked to ethacrynic acid and its brand equivalents (Edecrin), spanning 1997 through 2025. Of those, 64 (12.3%) listed death as an outcome and 212 (40.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 61% were female and 39% male; age distribution skews toward 65-74, with 132 reports in that bracket. The single most reported reaction is drug reaction with eosinophilia and systemic symptoms with 59 submissions, followed by off label use and nausea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.